AndroGel Benefits Not Worth Cardiac Risk, Jury Hears

Law360, Chicago (July 17, 2017, 8:11 PM EDT) -- A man suing AbbVie Inc. over its testosterone replacement therapy, AndroGel, told an Illinois federal jury Monday that the benefits he received from using the gel did not outweigh its risk of heart attack.

As his side wrapped up Monday, Jesse Mitchell personally made his case to the jury, which is considering whether AbbVie did enough to warn doctors about a risk of heart attack and other cardiac problems that some studies have connected to the drug.

Mitchell, who had a heart attack after using AndroGel for several years, told jurors that it helped him regain some energy after he began...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!